Skip to main content

Table 1 Baseline demographics

From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

 

ITT analysis set (all randomized)

 ≥ 90% methylation group

< 90% methylation group

 

Placebo (n = 102)

ZYN002 (n = 110)

Total (N = 212)

Placebo (n = 77)

ZYN002 (n = 92)

Total (n = 169)

Placebo (n = 25)

ZYN002 (n = 17)

Total

(n = 42)

Age (years)

 Mean

9.8

9.6

9.7

9.6

9.2

9.4

10.4

12.1

11.1

 Median (min, max)

10.0 (3, 17)

9.0 (3, 17)

10.0 (3, 17)

9.0 (3, 17)

9.0 (3, 17)

9.0 (3, 17)

11.0 (5, 16)

12.0 (5, 17)

11.0 (5, 17)

Sex—males, n (%)

78 (76.5)

81 (73.6)

159 (75.0)

54 (70.1)

65 (70.7)

119 (70.4)

24 (96.0)

15 (88.2)

39 (92.9)

Weight (kg)

 Median (min, max)

34.3

(15.6, 104.7)

36.8

(14.6, 87.0)

35.7

(14.6, 104.7)

33.9

(15.6, 104.7)

35.7

(14.6, 87.0)

35.0

(14.6, 104.7)

40.3

(21.9, 79.3)

50.0

(21.4, 66.4)

41.5

(21.4, 79.3)

Weight category

 > 35 kg, n (%)

49 (48.0)

61 (55.5)

110 (51.9)

35 (45.5)

49 (53.3)

84 (49.7)

14 (56.0)

12 (70.6)

26 (61.9)

ADOS®-2

 Comparison scorea

  Median (min, max)

7.0 (1, 10)

7.0 (1, 10)

7.0 (1, 10)

8.0 (1, 10)

7.0 (1, 10)

7.0 (1, 10)

6.0 (1, 10)

7.0 (3, 10)

7.0 (1, 10)

 Comparison score

 Categories,a n (%)

  Minimal/no evidence

9 (9.1)

9 (8.4)

18 (8.7)

6 (7.9)

9 (10.0)

15 (9.0)

3 (13.0)

0

3 (7.7)

  Mild

11 (11.1)

11 (10.3)

22 (10.7)

9 (11.8)

10 (11.1)

19 (11.4)

2 (8.7)

1 (6.3)

3 (7.7)

  Moderate

29 (29.3)

37 (34.6)

66 (32.0)

19 (25.0)

30 (33.3)

49 (29.5)

10 (43.5)

6 (37.5)

16 (41.0)

  Severe

45 (45.5)

47 (43.9)

92 (44.7)

37 (48.7)

41 (45.6)

78 (47.0)

8 (34.8)

6 (37.5)

14 (35.9)

  Not applicable

5 (5.1)

3 (2.8)

8 (3.9)

5 (6.6)

0

5 (3.0)

0

3 (18.8)

3 (7.7)

  Missing

3

3

6

1

2

3

2

1

3

VABS-3

 Overall—adaptive behavior composite scores

  n

100

102

202

76

84

160

24

17

41

  Median (min, max)

53.5 (25, 93)

51.1 (23, 119)

52.0 (23, 119)

51.5 (24, 119)

51.5 (24, 119)

51.5 (24, 119)

60.0 (27, 84)

47.0 (23, 74)

57.0 (23, 84)

  1. ADOS®-2 Autism Diagnostic Observation Schedule®-2, VABS-3 Vineland Adaptive Behavior Scales™, 3rd Edition
  2. aComparison score categories: minimal/no evidence = 1 or 2, mild = 3 or 4, moderate = 5 to 7, severe = 8 to 10